Eleni Karamouza

Antidrug Antibodies Against Immune Checkpoint Blockers: Impairment of Drug Efficacy or Indication of Immune Activation?

Diego Enrico, Angélo Paci, Nathalie Chaput et al. · Clinical Cancer Research · 2019 · 73 citations · Full text

Life Sciences, Immunology, Oncology +17

CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data

Eleni Karamouza, Rosalind Glasspool, Caroline Kelly et al. · Cancers · 2023 · 21 citations · Full text

Medicine, Biostatistics, Oncology +17

Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial

J. Bourhis, A. Auperin, Christian Borel et al. · The Lancet · 2025 · 18 citations

Medicine, Oncology, Surgery +9

751P Survival prognostic and surrogate values of the early modeled CA-125 KELIM in newly diagnosed advanced ovarian cancer: Data from the GCIG meta-analysis group

Pauline Corbaux, Benoît You, Rosalind Glasspool et al. · Annals of Oncology · 2021 · 13 citations

Medicine, Gynecology, Oncology +15

Early toxicity of moderately hypofractionated radiation therapy in breast cancer patients receiving locoregional irradiation: First results of the UNICANCER HypoG-01 phase III trial

Thomas Brion, Robabeh Ghodssi-Ghassemabadi, Guillaume Auzac et al. · Radiotherapy and Oncology · 2025 · 11 citations

Medicine, Oncology, Radiation Oncology +14